Compare Manchester United PLC (MANU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs BIO-TECHNE Corp — how do they compare? Manchester United PLC trades at $22.48 (market cap $3.80B), while BIO-TECHNE Corp trades at $71.69 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 2.9× Manchester United PLC's market cap, and Manchester United PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals.
| MANU | TECH | |
|---|---|---|
Market Cap | $3.80B | $11.16B |
Sector | Media | Health |
52-Week High | $23.53 | $72.12 |
52-Week Low | $15.10 | $43.31 |
Enterprise Value | $4.72B | $11.24B |
Dividend Yield | 1.26% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.05, down 0.81% today, with a bullish technical signal from moving averages but mixed recent earnings performance. Revenue grew to $667M in 2025, yet net losses persist at -$33M. The company is advancing a new 100,000-seat stadium project, a key long-term growth driver, while securing Champions League qualification boosts future revenue prospects.
Outlook hinges on stadium development execution and sustained sporting success to drive profitability. Risks include high debt levels and inconsistent earnings. Analysts are cautiously optimistic with 40% buy ratings, but investors should monitor cash flow trends amid significant capital expenditures.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
